NEW YORK — T2 Biosystems this week said in documents filed with the US Securities and Exchange Commission that it has engaged an advisory firm to sell the company and its assets, including its patents and other intellectual property. Earlier this week, T2 announced it had laid off substantially all of its employees, fired its top executives, and reappointed those executives to part-time consulting roles.
Danaher this week announced that its board of directors has approved a regular quarterly cash dividend of $.32 per share of its common stock, payable on April 25 to holders of record on March 28.
Agilent Technologies said this week that its board of directors has approved a quarterly dividend of $.25 per share of its common stock, payable on April 23 to shareholders of record on April 1.
Saudi German Health said this week that it has signed a memorandum of understanding with Becton Dickinson to introduce diagnostic technologies in the Saudi region. As part of the deal, technologies such as BD's Bactec blood culture system, its antimicrobial susceptibility testing platform called Phoenix, and the firm's Epicenter microbiology data management system will be introduced to the region. BD's MALDI-TOF mass spectrometry system for identifying microorganisms will also be introduced in the area. Financial and other terms of the agreement were not disclosed. In a statement, the partners said the MOU allows providers in the region to deliver accurate diagnostics more quickly, leading to better patient outcomes. About 2 million patients will benefit from the deal, they added. Saudi German Health provides healthcare in the Middle East and North Africa.
German test components supplier Applyo Jena said this week that it has completed a Series A funding round that was led by Bosch Ventures with participation from LBBW Venture Capital. The firms did not disclose the amount that was raised. Applyo Jena uses freeze-drying technology to offer lyophilized reagents and enzymes with extended shelf lives, stability at ambient temperatures, and improved ease of use compared to liquid components, and it plans to use the Series A funding to accelerate its international expansion and offer its components for use in the diagnostic, pharmaceutical, and life sciences markets.
AccessDx Laboratory, a CLIA-certified, CAP-accredited, and New York State Department of Health-approved diagnostic laboratory, this week announced an expanded integration with the PointClickCare healthcare technology platform. The integration allows for the delivery of pharmacogenomic (PGx) risk assessments, advanced diagnostic test results, and ongoing PGx monitoring to healthcare providers in the PointClickCare network, which provides long-term care to seniors.
Wellness company Hims & Hers said this week that it has acquired the company Sigmund NJ, which operates under the name Trybe Labs, and it plans to use the acquisition to offer within the next year testing using at-home blood draws. Terms of the deal were not disclosed, although Hims & Hers said that the transaction was completed through cash on hand.
The firm said that it will use blood lancet-based sample collection to provide tests for hormone levels, cardiac risk, stress markers, cholesterol, liver and thyroid function, and prostate health. It said that the deal also will allow it to offer a wider range of personalized treatments and expand into clinical offerings for the support of low testosterone, perimenopausal, and menopausal patients, and the firm said that it plans to use de-identified patient data to support the development of artificial intelligence-supported personalized healthcare offerings.
Abbott said this week that its board of directors has declared a quarterly dividend of $.59 per share. The cash dividend will be paid on May 15 to shareholders of record as of April 15.
PAVmed subsidiary Lucid Diagnostics announced this week that it has entered into its first concierge medicine contract with LEAA Health. The contract provides LEAA Health's members with access to Lucid's EsoGuard Esophageal DNA test as part of their personalized care service on a cash-pay basis. Lucid said it aims to drive "contractually guaranteed revenue by capitalizing on the growing demand for prevention-focused healthcare services in the expanding concierge medicine market."
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.